Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

• Published in: Lipids in health and disease 2016-07, Vol.15 (1), p.116-116, Article 116
• Main Authors: Brinton, Eliot A, Triscari, Joseph, Brudi, Philippe, Chen, Erluo, Johnson-Levonas, Amy O, Sisk, Christine McCrary, Ruck, Rae Ann, MacLean, Alexandra A, Maccubbin, Darbie, Mitchel, Yale B
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100 - blood; Apolipoproteins; Blood cholesterol; Blood Glucose - metabolism; Cardiovascular diseases; Care and treatment; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Delayed-Action Preparations - therapeutic use; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Double-Blind Method; Fasting; Female; Humans; Hyperlipidemias - blood; Hyperlipidemias - drug therapy; Hyperlipidemias - physiopathology; Hypoglycemic Agents - therapeutic use; Hypolipidemic Agents - therapeutic use; Indoles - therapeutic use; Insulin - blood; Low density lipoproteins; Male; Middle Aged; Niacin - therapeutic use; Patient outcomes; Physiological aspects; Triglycerides - blood; Type 2 diabetes
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-016-0282-8

LDL-C, non-HDL-C and ApoB levels are inter-correlated and all predict risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM) and/or high TG. These levels are lowered by extended-release niacin (ERN), and changes in the ratios of these levels may affect ASCVD risk. This analysis examined the effects of extended-release niacin/laropiprant (ERN/LRPT) on the relationships between apoB:LDL-C and apoB:non-HDL-C in patients with T2DM. T2DM patients (n = 796) had LDL-C ≥1.55 and